Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heparin, DDAVP and the bleeding time.

S Schulman1, H Johnsson

  • 1Department of Internal Medicine, Karolinska Hospital, Stockholm, Sweden.

Thrombosis and Haemostasis
|March 4, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Splanchnic vein thrombosis with and without myeloproliferative neoplasms: a comparative cohort study.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Anticoagulation strategies and risk of bleeding events in critically ill COVID-19 patients.

Medicina intensiva·2021
Same author

Anticoagulation strategies and risk of bleeding events in critically ill COVID-19 patients.

Medicina intensiva·2021
Same author

Associations of thrombocytopenia, transaminase elevations, and transfusion with laboratory coagulation tests in women with preeclampsia: a cross-sectional study.

International journal of obstetric anesthesia·2021
Same author

Lemierre syndrome - treat with antibiotics, anticoagulants or both?

Journal of internal medicine·2020
Same author

Assessment of clinically relevant bleeding as a surrogate outcome for major bleeding: validation by meta-analysis of randomized controlled trials.

Journal of thrombosis and haemostasis : JTH·2017
Same journal

Discontinuation of Oral Anticoagulation After Successful Catheter Ablation for Atrial Fibrillation: Meta-analysis of Randomized Clinical Trials.

Thrombosis and haemostasis·2026
Same journal

Novel/Recurrent Variants in Pakistani Glanzmann Thrombasthenia and Glanzmann-like bleeding diathesis: Insights from NGS Analysis.

Thrombosis and haemostasis·2026
Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026
Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026
Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026
Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026
See all related articles

Heparin treatment prolonged bleeding time in patients with venous thromboembolism. Desmopressin (DDAVP) partially reversed this effect, suggesting its use for managing heparin-induced bleeding complications.

Area of Science:

  • Pharmacology
  • Hematology
  • Clinical Medicine

Background:

  • Heparin is a common anticoagulant used for venous thromboembolism.
  • Heparin therapy can lead to prolonged bleeding times.
  • Managing bleeding complications during anticoagulation is clinically important.

Purpose of the Study:

  • To investigate the effect of desmopressin (DDAVP) on heparin-induced prolongation of bleeding time.
  • To evaluate DDAVP as a potential intervention for hemorrhagic issues during heparin therapy.

Main Methods:

  • A randomized, double-blind study was conducted on 20 patients with acute venous thromboembolism.
  • Patients received heparin followed by either DDAVP (0.3 mcg/kg) or placebo infusion.
  • Bleeding time and activated partial thromboplastin time (APTT) were measured.

Related Experiment Videos

Main Results:

  • Heparin significantly prolonged bleeding time by an average of 90%.
  • DDAVP shortened bleeding time by 23%, while placebo had a minimal effect (-2%).
  • DDAVP also shortened APTT, unlike placebo.

Conclusions:

  • Desmopressin (DDAVP) partially reverses the bleeding time prolongation caused by heparin.
  • DDAVP may be a viable option for managing bleeding complications associated with heparin treatment.